Form 4: Foresite Labs Boosts ALUMIS Stake

Foresite Labs, a 10% owner and director, reported an acquisition of 72,212 shares of ALUMIS INC. common stock at $7.38 per share.

Summary

• Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC, both 10% owners and directors of ALUMIS INC. (ALMS), reported an acquisition of common stock.
• On November 21, 2025, 72,212 shares of ALUMIS INC. common stock were acquired at a price of $7.38 per share.
• Following this transaction, the reporting persons indirectly beneficially own a total of 15,778,040 shares of ALUMIS INC. common stock through various Foresite Capital funds and entities.
• James B. Tananbaum, through his roles in the general partners and managing members of these entities, may be deemed to have sole voting and dispositive power over these shares.
• The reporting persons disclaim the existence of a 'group' as defined in Rule 13d-5 of the Securities Exchange Act of 1934 and disclaim beneficial ownership of shares held by the funds, except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The acquisition of shares by a 10% owner and director is generally a positive signal, indicating confidence in the company's valuation and future prospects. The transaction value is significant, reinforcing this positive sentiment.

Positives

• Significant insider buying by a 10% owner and director, indicating confidence in the company's future prospects.
• The purchase price of $7.38 per share provides a clear valuation point for this insider transaction.
• Increased alignment of interests between a major institutional investor/director and other shareholders.

Risks

• The reporting persons disclaim the existence of a 'group' as defined in Rule 13d-5 of the Exchange Act, which could be a point of regulatory scrutiny if their actions suggest otherwise.
• Beneficial ownership is disclaimed by some reporting persons except to the extent of their pecuniary interest, which could complicate understanding the full extent of control or influence.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the transaction itself.

Industry Context

Insider purchases by significant shareholders and directors, especially by venture capital or investment firms like Foresite Labs, often signal confidence in a company's long-term strategy or upcoming catalysts. Such transactions can be viewed positively by the market, suggesting that those with deep insight into the company's operations see value at the current price.

Comparison to Industry Standards

• This is an insider transaction report (Form 4), not a financial performance report. Therefore, direct comparisons to industry-standard financial metrics or project results of comparable companies are not applicable.
• Insider buying activity is generally seen as a positive indicator, aligning with best practices for corporate governance where management and significant shareholders demonstrate conviction in the company's value.

Stakeholder Impact

• Shareholders: Potentially positive, as insider buying can boost investor confidence and signal undervaluation.
• Management: Increased alignment with a significant institutional investor and director.

Next Steps

• Investors will likely monitor future Form 4 filings from Foresite Labs and its affiliates for further changes in their holdings.

Key Dates

Recommendation

The reported insider purchase by a 10% owner and director, Foresite Labs, indicates a vote of confidence in ALUMIS INC. at the acquisition price of $7.38 per share. This typically signals that those closest to the company see value. However, a single Form 4 filing, without additional comprehensive financial or strategic updates, is insufficient to warrant a 'buy' or 'strong buy' recommendation. It primarily reinforces a 'hold' position for existing investors and suggests potential value for those considering the stock, pending further comprehensive analysis of the company's fundamentals and market conditions.

Keywords

ALUMIS INC., ALMS, Foresite Labs, Insider Trading, Stock Purchase, Form 4, Beneficial Ownership, Director, 10% Owner